Michael Nagler

Prof. Dr. Michael Nagler

Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2016 in Blood
Verified
Journal Article
Open access
PDF file
Michael NaglerMichael Nagler
Michael Nagler
LBLucas M. Bachmann
Lucas M. Bachmann
HCHugo Ten Cate
Hugo Ten Cate
ACArina Ten Cate-Hoek
Arina Ten Cate-Hoek
Key Points: Immunoassays used to diagnose heparin-induced thrombocytopenia vary substantially with regard to the specific test characteristics. High sensitivity (>95%) in combination with high specificity (>90%) was found in only 5 tests.

1 August 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SJSabrina Jegerlehner
Sabrina Jegerlehner
FSFranziska Suter-Riniker
Franziska Suter-Riniker
PJPhilipp Jent
Philipp Jent
PBPascal Bittel
Pascal Bittel
Michael NaglerMichael Nagler
Michael Nagler
Laboratory tests are a mainstay in managing the COVID-19 pandemic, and high hopes are placed on rapid antigen tests. However, the accuracy of rapid antigen tests in real-life clinical settings is unclear because adequately designed diagnostic accuracy studies are essentially lacking. The aim of this study was to assess the accuracy of a rapid antigen test in diagnosing SARS-CoV-2 infection in a primary/secondary care testing facility. Consecutive individuals presenting at a COVID-19 testing facility affiliated to a Swiss University Hospital were recruited (n = 1465%). Nasopharyngeal swabs were obtained, and the Roche/SD Biosensor rapid antigen test was conducted in parallel with two real-time PCR tests (reference standard). Among the 1465 patients recruited, RT-PCR was positive in 141 individuals, corresponding to a prevalence of 9.6%. The Roche/SD Biosensor rapid antigen test was positive in 94 patients (6.4%), and negative in 1368 individuals (93.4%; insufficient sample material in 3 patients). The overall sensitivity of the rapid antigen test was 65.3% (95% confidence interval [CI] 56.8–73.1), the specificity was 99.9% (95% CI 99.5–100.0). In asymptomatic individuals, the sensitivity was 44.0% (95% CI 24.4–65.1). The accuracy of the SARS-CoV-2 Roche/SD Biosensor rapid antigen test in diagnosing SARS-CoV-2 infections in a primary/secondary care testing facility was considerably lower compared with the manufacturer's data. Widespread application in such a setting might lead to a considerable number of individuals falsely classified as SARS-CoV-2 negative.

4 August 2020 in Circulation
Verified
Journal Article
Open access
PDF file
GGGiuseppe Gargiulo
Giuseppe Gargiulo
GEGiovanni Esposito
Giovanni Esposito
MAMarisa Avvedimento
Marisa Avvedimento
Michael NaglerMichael Nagler
Michael Nagler
PMPietro Minuz
Pietro Minuz
MVMarco Valgimigli
Marco Valgimigli
Background: Standard administration of newer oral P2Y 12 inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention. We aimed to investigate the effects of cangrelor, tirofiban, and prasugrel, administered as chewed or integral loading dose, on IPA in patients undergoing primary percutaneous coronary intervention. Methods: The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention) is an investigator-initiated, multicenter, open-label, randomized study. A total of 122 P2Y 12 -naive patients with ST-segment–elevation myocardial infarction were randomly allocated (1:1:1) to cangrelor (n=40), tirofiban (n=40) (both administered as bolus and 2-hour infusion followed by 60 mg of prasugrel), or 60-mg loading dose of prasugrel (n=42). The latter group underwent an immediate 1:1 subrandomization to chewed (n=21) or integral (n=21) tablets administration. The trial was powered to test 3 hypotheses (noninferiority of cangrelor compared with tirofiban using a noninferiority margin of 9%, superiority of both tirofiban and cangrelor compared with chewed prasugrel, and superiority of chewed prasugrel as compared with integral prasugrel, each with α=0.016 for the primary end point, which was 30-minute IPA at light transmittance aggregometry in response to 20 μmol/L adenosine diphosphate. Results: At 30 minutes, cangrelor did not satisfy noninferiority compared with tirofiban, which yielded superior IPA over cangrelor (95.0±8.9 versus 34.1±22.5; P <0.001). Cangrelor or tirofiban were both superior to chewed prasugrel (IPA, 10.5±11.0; P <0.001 for both comparisons), which did not provide higher IPA over integral prasugrel (6.3±11.4; P =0.47), despite yielding higher prasugrel active metabolite concentration (ng/mL; 62.3±82.6 versus 17.1±43.5; P =0.016). Conclusions: Cangrelor provided inferior IPA compared with tirofiban; both treatments yielded greater IPA compared with chewed prasugrel, which led to higher active metabolite concentration but not greater IPA compared with integral prasugrel. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02978040; URL: https://www.clinicaltrialsregister.eu ; EudraCT 2017-001065-24.

1 April 2012 in Thrombosis Research
Verified
Journal Article
Closed access
Michael NaglerMichael Nagler
Michael Nagler
MHMichael Haslauer
Michael Haslauer
WWWalter A. Wuillemin
Walter A. Wuillemin

11 April 2020 in Swiss Medical Weekly
Verified
Journal Article
Open access
PDF file
ACAlessandro Casini
Alessandro Casini
LALorenzo Alberio
Lorenzo Alberio
AAAnne Angelillo-Scherrer
Anne Angelillo-Scherrer
PFPierre Fontana
Pierre Fontana
BGBernhard Gerber
Bernhard Gerber
LALars Asmis
Lars Asmis
Based on the available literature and published recommendations from international societies, the Working Party on Hemostasis (Swiss Society of Hematology) has prepared recommendations for pharmacological thromboprophylaxis in COVID-19 patients in the acute setting.

25 April 2019 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MAMarcel Adler
Marcel Adler
JKJonas Kaufmann
Jonas Kaufmann
LALorenzo Alberio
Lorenzo Alberio
Michael NaglerMichael Nagler
Michael Nagler
Background Bleeding assessment tools (BAT) have been widely implemented in the work‐up of patients with suspected bleeding disorders. However, diagnostic BAT utility regarding platelet function disorders is still elusive. Aim We aimed to assess the diagnostic value of the International Society on Thrombosis and Haemostasis BAT (ISTH‐BAT) for platelet function disorders in clinical practice. Methods The clinical characteristics and laboratory data of all consecutive patients referred between January 2012 and March 2017 to an outpatient unit of a university hospital with a suspected bleeding disorder were prospectively collected. The diagnostic work‐up was performed according to current recommendations following a pre‐specified protocol and platelet function was tested using light transmission aggregometry as well as flow cytometry. Results Five hundred and fifty‐five patients were assessed, 66.9% were female, median age was 43.7 years (inter‐quartile range [IQR] 29.3, 61.7). Confirmed platelet function disorder was diagnosed in 54 patients (9.7%), possible platelet function disorder in 64 patients (11.5%), and other disorders in 170 patients (30.6%). Median scoring of the ISTH‐BAT was 2 in patients without a bleeding disorder (IQR 1, 3), 4 in patients with a possible platelet function disorder (2, 7), and 7 in patients with confirmed platelet function disorder (5, 9). Area under the ROC curve (AUC) was 0.75 (95% CI 0.70, 0.80). Conclusions Presence of a platelet function disorder was associated with substantially higher BAT scorings compared to patients without. Our data suggest that the ISTH‐BAT provides a useful screening tool for patients with suspected platelet function disorders.